CWIEME 2025 WACKER Unveils Conductive Silicone Innovation for Power Plant Generators

ELASTOSIL® N 9189: Electrically Conductive Silicone for Power Plant Generators ELASTOSIL® N 9189 is a one-component, room-temperature vulcanizing (RTV-1) silicone rubber that cures upon exposure to atmospheric humidity, releasing only alcohol during the process. This tin-free formulation offers significant processing…

Read MoreCWIEME 2025 WACKER Unveils Conductive Silicone Innovation for Power Plant Generators

Albemarle Releases 2024 Sustainability Report Highlighting Carbon, Water, and Customer Goals

Albemarle Corporation 2024 Sustainability Report: A Comprehensive Overview Albemarle Corporation a global leader in specialty chemicals and a key player in the supply of essential elements for mobility, energy, connectivity, and health, has published its 2024 Sustainability Report titled “Values-Led,…

Read MoreAlbemarle Releases 2024 Sustainability Report Highlighting Carbon, Water, and Customer Goals

Marketing Authorization Application for Gadoquatrane Submitted in Japan

Marketing Authorization Application for Gadoquatrane Submitted in Japan Bayer has officially submitted a marketing authorization application to Japan’s Ministry of Health, Labour and Welfare (MHLW) for gadoquatrane, its investigational gadolinium-based contrast agent designed for use in magnetic resonance imaging (MRI).…

Read MoreMarketing Authorization Application for Gadoquatrane Submitted in Japan

Germany’s Shisha Market Poised for Rapid Growth as 83% of Hospitality Venues Forecast Surge

Germany’s Shisha Market Set for Rapid Expansion as Hospitality Sector Embraces Innovation Market The hospitality sector in Germany is on the brink of a transformative shift as demand for shisha continues to climb at an unprecedented pace. According to new…

Read MoreGermany’s Shisha Market Poised for Rapid Growth as 83% of Hospitality Venues Forecast Surge

FDA Grants Priority Review to Sevabertinib (BAY 2927088) for Treating HER2-Mutant Non-Small Cell Lung Cancer

Bayer’s Sevabertinib (BAY 2927088) Receives FDA Priority Review for HER2-Mutant Non-Small Cell Lung Cancer FDA Bayer has announced that its investigational compound, sevabertinib (BAY 2927088), has been granted Priority Review status by the U.S. Food and Drug Administration (FDA) for…

Read MoreFDA Grants Priority Review to Sevabertinib (BAY 2927088) for Treating HER2-Mutant Non-Small Cell Lung Cancer